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during pancytopenic phase after transplant.
Conclusions: By undertaking this study we will ﬁnd out
whether there is preliminary support for the effectiveness of
the currently used in-hospital exercise program for people
who are undergoing HSCT with various levels of pancyto-
penia. We will also determine whether higher compliance
with an exercise program is associated with better functional
outcomes.
Clinical Relevance: Since there are few studies supporting
patient exercising or performing functional activities with
acute pancytopenia, we hope to lay some groundwork in this
area for further research into this and other similar patient
populations.207
Supporting Siblings Through the Allogeneic
Hematopoietic Cell Transplant Process: The Perspectives
of Minor and Young Adult Siblings of Successful
Transplant Recipients
Jennifer P. D'Auria 1, Cammie Moore Presler 2,
Kimberly A. Kasow 2. 1 School of Nursing, University of North
Carolina, Chapel Hill, NC; 2 Pediatrics, University of North
Carolina, Chapel Hill, NC
Allogeneic hematopoietic cell transplantation (AHCT)
remains an arduous medical therapy that challenges the
physical and psychological reserves of the family unit at
all stages of the process. Few studies have focused on the
perspectives of healthy siblings regarding the types of
support needed as they journey across the AHCT trajec-
tory. This IRB-approved qualitative study explored the
minor/young adult siblings’ experiences of the AHSCT
experience, speciﬁcally the types of support they would
recommend to other siblings going through this experi-
ence. A retrospective interview approach was used to
capture the perspectives of 12 siblings of successful
pediatric matched sibling donor transplants at our insti-
tution between January 1999 and September 2009. All 12
participants had been HLA tested, with 8 serving as
matched sibling donors. Median age at the time of the
AHCT was 12 years (yrs) (range, 2-23 yrs) and at the time
of the interview was 16 yrs (range, 10-30 yrs). The median
time between donation and the interview was 6 yrs
(range, 2-10 yrs). A grounded theory approach was used
to analyze and interpret transcribed interview data. Semi-
structured private interviews, demographic data, and ﬁeld
notes were the primary sources of data. Seven themes
emerged: (a) being included in the health care “family”,
(b) being involved with the ill sibling, (c) being prepared
for each step of the process, (d) meeting others who have
been through the experience, (e) receiving reassurance
and hope, (f) drawing on the support of parents/family
after the procedure, and (g) talking to others about their
experiences. The stories of these participants supported
that the ill sibling, the family, and the health care team all
play an important role in supporting them across the
transplant trajectory. Interventions must be designed to
focus on the unique physical, emotional and social needs
of siblings to help them make sense of the transplant
process. Age-appropriate educational materials will
provide youth with accurate information as well as a way
to help them ask questions and express emotions. Finally,
providing professional support that extends beyond the
transplant itself is essential for helping them piece
together the meaning of the transplant and related events
for their lives.208
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Pediatric cancer survivorship is a growing subspecialty
however few clinicians focus solely on survivors of hema-
topoietic stem cell transplant (HSCT). There were 100,000
HSCT survivors in the US in 2009 and an estimated 250,000
survivors by 2020 (CIBMTR data). Approximately 80% of
pediatric HSCT patients survive at least two years post
transplant and are expected to become long term survivors.
Post-transplant complications are the third cause of death in
this patient population. The focus of clinical management
then shifts toward decreasing the morbidity of long-term
treatment effects through early detection and intervention.
We piloted a multi-disciplinary pediatric HSCT survivor
clinic. From more than 400 patients transplanted at our
center between 2003 and 2011, 32 patients were seen at one
of 5 long-term follow-up clinic days in July and August 2012.
Eligible patients were at least one year post HSCT and off
immune suppression, and were invited based on availability.
Fourteen patients were male, 18 female. Average age at time
of transplant was 6.7 years (0.1-17 years); average age at time
of survivor clinic was 10.7 years (range 2-20 years). Most
were greater than 4 years post HSCT (range 17-117 months)
and had undergone allogeneic HSCT. The most common late
effects detected were musculoskeletal (59%, primarily
vitamin D deﬁciency and bone mineral loss), and endocrine
(56%). Cardiac late effects were seen in 2 patients and were
not life threatening (1 hypertension and 1 hyperlipidemia).
Pulmonary late effects were seen in 9% of patients, derma-
tologic in 12%, psychological in 18% and 44% were catego-
rized as other, mostly low vaccine titers. No second
malignancies were identiﬁed. School performance concerns
were common (n¼ 40%).
More than 40 referrals were generated to other pediatric
specialists as a result of our evaluation. A comprehensive
cancer summary with speciﬁc recommendations from the
multi-disciplinary team was mailed to each patient and
appropriate medical providers.
Late effects in the growing population of HSCT survivors
are common and, thus create an obligation to screen, apply
early interventions, and refer to appropriate specialists as
part of their post-transplant care.
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Background: With improved survival following pediatric
stem cell transplantation (SCT), long term effects of the
therapy including OP and ON need to be addressed. These
problems are known to occur in adult solid organ trans-
plantation and adult SCT but little is reported in the pediatric
literature. High-risk features associated with diminished
bone density include hypothyroidism, hypogonadism,
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hydroxy-vitamin D deﬁciency, total body irradiation, and
growth hormone deﬁciencies. This report is a single insti-
tutions retrospective analysis of bone density evaluation and
incidence of OP/ON following pediatric SCT.
Method: From 2003 to 2012, 17 patients undergoing allo-
geneic stem cell transplantation (5 AML, 8 ALL, 1 CML, 1 NHL,
2 aplastic anemia) received lipid proﬁle evaluation per-
formed at Loma Linda University Medical Center by a Roche
Modular System Photometric Assay and 25-OH vitamin D
analysis at Mayo Clinic, Rochester Minnesota. 15 of these
patients also had bone density testing by a dual-energy x-ray
absorptiometry (DEXA) scan. With osteoporosis and osteo-
penia deﬁned as Z score <-1 and <-2.5 respectively. 9
patients received stem cells from HLA matched unrelated
donors (MUD) and 8 HLA matched related sibling donors
(MRD). Patients were treated with: (14) 1200 cGy total body
irradiation, 1500mg/m2 etoposide, 120 mg/kg cyclophos-
phamide; (1) busulfan (16 doses), 200 mg/kg cyclophos-
phamide; (2) ATG, 200 mg/kg cyclophosphamide, 200 cGy
total body irradiation. GVHD prophylaxis was cyclosporine
for MRD or tacrolimus for MUD and short course metho-
trexate. Patient's age at testing ranged from 7 to 23 years,
mean 13.5 years.
Result: OP was extremely common after SCT with bone
density Z score of lower then -1 in 13/15 tested. 25-OH Vit D
was low in 15 /17 tested. Elevated cholesterol was present in
8/17 and cholesterol/HDL ratio (>3.5%) in 12/15 tested.
Stratiﬁcation of patients by history of chronic GVHD or
moderate to severe acute GVHD showed that while meta-
bolic abnormality was present in both groups, symptomatic
OP/ON were conﬁned to the chronic GVHD group. Among 4
patients with no history of GVHD, 2/4 had normal bone
density, 2/4 had normal lipids, and none had symptomatic
OP/ON. In contrast, among 13 patients with GVHD all 10/10
tested had diminished bone density, 9/10 tested had elevated
lipid ratios, and 5/13 had symptomatic OP/ON with 4
requiring surgery. Symptomatic OP/ON events resulted in the
need for joint replacement of the knees, hips and shoulders.
In addition, patients had fractures of the long bones needing
internal ﬁxation devices to help with the repair.
Conclusion: These results suggest that lipid metabolism
abnormalities and low Vit D levels are common after SCT and
interventions to normalize these abnormalities may have the
greatest impact on symptomatic ON/OP in patients with
GVHD.210
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Background: Neurocognitive function is vulnerable in the
formative pediatric years to transplant conditioning regimen
especially those using fractionated total body irradiation
(FTBI). However, FTBI improves disease free survival (DFS) in
lymphoid malignancies. Our institution has previously
described a novel conditioning regimen using low dose
single fraction TBI (SDTBI) delivered at a high dose rate. DFS
was comparable to recipients of fractionated TBI, and early
toxicities were minimal (Druley, BMT 2009). Our hypothesisis that SDTBI based myeloablative conditioning is associated
with less neurotoxicity and can preserve neurocognitive
functions in children.
Aim: To review neurocognitive function in children
following SDTBI (550 cGy) and cyclophosphamide- based
myeloablative transplant conditioning for hematologic
malignancies pre and 1 year post transplant.
Methods: A total of 45 consecutive children transplanted for
hematologic malignancies (ALL, AML, NHL) between March
1998 and January 2006 that survived beyond 1 year after
transplant were identiﬁed. The conditioning regimen con-
sisted of cyclophophamide 50 mg/kg on days -3 and -2, and
SDTBI (550 cGy) on day -1. Fifteen had neurocognitive testing
completed before and at least 1 year post transplant. This
testing comprised of a comparative analysis of IQ and neu-
rocognitive function using Wechsler intelligence scales
selected based on the child's age.
Result: Full scale (FSIQ), verbal (VIQ), and performance or
non-verbal (PIQ) IQs were compared. Using a greater than 1
SD loss (or greater than 15 point loss) criterion as a gross
marker for signiﬁcant decline at the individual patient level.
Fifteen patients had an average age was 10.7 years (range 1-
20.5). No patient showed a decline in FSIQwith the exception
of one. This child underwent a second myeloablative trans-
plant one year after the ﬁrst; FSIQ declined by 16 points. One
child's VIQ declined 23 points; two others’ PIQ declined by 16
and 21 points, respectively.
Conclusion: Among a limited cohort of SDTBI BMT, the
majority showed an overall stability or lack of signiﬁcant
decline in neurocognitive function one year post transplant.
In contrast, previous reports show decline one year post
transplant in children receiving FTBI (Phipps S et al, JCO
2008; Shah et al, PBC 2008). These data provide an initial
insight into the effects of SDTBI based conditioning on neu-
rocognition in children. Future studies will expand the
analysis to further analyze exposure to CNS toxic treatments
and to examine more detailed cognitive measures for
domain speciﬁc trends. We will also look at patients that
received FTBI and Bulsulfan/cyclosphosphamide.211
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Introduction: Hematopoietic stem cell transplantation
(HSCT) is an increasingly utilized treatment option for
adolescents with a wide range of life-threatening diagnoses.
Following discharge, adolescents who have undergone HSCT
must manage a complex treatment regimen including
numerous oral and/or intravenous medications. Suboptimal
adherence to this medication regimen may result in sub-
therapeutic medication exposure, potentially compromising
treatment effectiveness and, subsequently, increasing the
risk of adverse medical outcomes. During adolescence,
individuals are increasingly likely to experience stressors
